OOIR: Observatory of International Research

Papers

(The H4-Index of npj Breast Cancer is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer	672
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer	318
Biological correlates associated with high-risk breast cancer patients identified using a computational method	190
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer	125
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination	123
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers	113
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence	103
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab	97
CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer	90
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer	88
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer	87
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer	85
International survey on invasive lobular breast cancer identifies priority research questions	73
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment	68
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021	66
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	65
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients	64
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)	63
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer	62
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice	58
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial	57
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events	55
Circulating tumor DNA validity and potential uses in metastatic breast cancer	50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer	49
Host-derived interleukin-1α drives tumor immunosuppression by reprogramming tumor-associated myeloid cells	47

Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions	47
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer	47
Breastfeeding attributable fraction of triple negative breast cancer in the US	45
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays	45
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines	44
Survival outcomes after omission of surgery for ductal carcinoma in situ	42
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study	42
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)	42
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer	40
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer	40
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer	38
Temporal evolution of breast cancer brain metastases treatments and outcomes	37
Understanding metastasis mixed-treatment responses through genomic analyses	37
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center	37